The Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial, which examined the suppression effect of the SGLT2 inhibitor dapagliflozin on CKD progression [18], included patients with CKD receiving angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) with a baseline eGFR of 25–75 mL/min/1.73 m2 (mean [SD] 43.1 [12.4]) and a baseline UACR of 200–5000 mg/gCr (median 949.3). Here, SLC5A2 is linked to chronic kidney disease.